24/7 Market News Snapshot 05 June, 2025 – MAIA Biotechnology, Inc. (NYSE:MAIA)

June 5, 2025

DENVER, Colo., 05 June, 2025 (www.247marketnews.com) – (NYSE:MAIA) are discussed in this article.
MAIA Biotechnology, Inc. has opened today’s trading session at $1.95, demonstrating a notable increase of 8.47% from the previous close of $1.76, with current trading hovering at $1.909. The day’s trading volume reached 1.80 million shares, reflecting heightened interest among investors. Observers suggest that resistance levels may present themselves around the $2.00 mark, while support appears established near the previous closing price. Monitoring both volume shifts and price trends will be crucial for assessing future market direction, particularly as the current trading activity exhibits a positive outlook.

In a significant development for the biotechnology sector, MAIA Biotechnology has reported encouraging results from its Phase 2 clinical trial, THIO-101, for advanced non-small cell lung cancer (NSCLC). A noteworthy achievement in the trial is the emergence of a new partial response in a patient following 20 months of treatment with ateganosine (THIO) in conjunction with Regeneron’s immune checkpoint inhibitor cemiplimab (Libtayo®). This response indicates a reduction in tumor size by at least 30%, marking a promising advance for patients who have previously been unresponsive to conventional therapies.

Dr. Vlad Vitoc, Chairman and CEO of MAIA, expressed optimism about the findings, emphasizing the significance of observing a stable disease for over twenty months before a partial response was recorded. He highlighted the rarity of such long-term positive outcomes in heavily pretreated NSCLC patients, particularly where traditional therapies have often resulted in a grim prognosis.

With the data cutoff indicating a median overall survival of 17.8 months among trial participants, MAIA urges stakeholders to anticipate the expansion of the THIO-101 study. This extension aims to further evaluate the treatment’s effectiveness for advanced NSCLC patients who have displayed resistance to prior interventions. As ateganosine continues to emerge as a groundbreaking telomere-targeting agent, MAIA remains dedicated to advancing innovative immunotherapy solutions to enhance survival rates and improve the quality of life for cancer patients.

Related news for (MAIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.